AbbVie Broadens Qulipta Migraine Indication As Anti-CGRP Competition Grows

Approval Comes Month After New Pfizer Product

AbbVie’s migraine franchise expanded with US FDA approval of Qulipta for chronic migraine prevention, but its CGRP inhibitors are facing off against a pair of rivals acquired by Pfizer last year.

Tired african-american business woman with headache at office, feeling sick at work, copy space
Qulipta cut headache days significantly for chronic migraine sufferers

AbbVie Inc. has a multi-modality migraine drug franchise, now expanded with a broader US label for its oral CGRP inhibitor Qulipta (atogepant) in migraine prevention, but the company is facing tough competition in the anti-CGRP space, which recently added yet another approved product with a first-in-class route of administration.

Qulipta won US Food and Drug Administration approval for the prevention of episodic migraine (14 headaches or fewer per month)...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip